IMGT/mAb-DB card

Version: 2.0.4 (2023-04-14)

Citing IMGT/mAb-DB

Manso T., Kushwaha A., Abdollahi N., Duroux P., Giudicelli V. and Kossida S. Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB. Front Immunol., 14 (2023). DOI 10.3389/fimmu.2023.1129323

Poiron C., Wu Y., Ginestoux C., Ehrenmann, Duroux P. and Lefranc M.-P. IMGT/mAb-DB: the IMGT® database for therapeutic monoclonal antibodies. JOBIM 2010, Paper 13 (2010). Abstract

Cambon M., Cherouali K., Kushwaha A., Giudicelli V., Duroux P., Kossida S. and Lefranc M.-P. IMGT/mAb-DB and IMGT/2Dstructure-DB for IMGT standard definition of an antibody: from receptor to amino acid changes. JOBIM 2018, Poster 201 (2018). Abstract

IMGT/mAb-DB ID	418
INN	fasinumab
INN Number	9589
INN Prop. List	107 (2012)
INN Rec. List	69 (2013)
Common name	REGN475, SAR164877
Proprietary name
Species	Homo sapiens
IMGT receptor type	IG
Format (legend)
Receptor identification	IgG4 - kappa
Radiolabelled / Conjugated / Fused
IMGT/2Dstructure-DB	9589
IMGT/3Dstructure-DB
Specificity target name and species	NGF (nerve growth factor, nerve growth factor beta polypeptide, NGFB, beta-NGF) [Homo sapiens]
Development Technology	VelocImmune®
Origin clone species
Origin clone name

Company	Regeneron Pharmaceuticals Inc. (Tarrytown NY USA)
Expression system
Application	Therapeutic
Clinical domain	Immunology
Mechanism of action
Clinical indication	Osteoarthritis (OA)
Development status	Phase III
Regulatory agency status and year

Company	Regeneron Pharmaceuticals Inc. (Tarrytown NY USA)
Expression system
Application	Therapeutic
Clinical domain	Neurology
Mechanism of action
Clinical indication	Pain chronic
Development status	Phase III
Regulatory agency status and year

Clinical trials
Authority decisions
External links
Biosimilars

Format legend:

IMGT/mAb-DB query | IMGT/mAb-DB documentation